The estimated Net Worth of Daniel R Omstead is at least 4.29 百万$ dollars as of 25 September 2023. Mr. Omstead owns over 10,096 units of abrdn Healthcare Opportunities Fund stock worth over 4,292,066$ and over the last 20 years he sold THQ stock worth over 0$. In addition, he makes 0$ as President、 Trustee at abrdn Healthcare Opportunities Fund.
Daniel has made over 45 trades of the abrdn Healthcare Opportunities Fund stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 10,096 units of THQ stock worth 125,089$ on 25 September 2023.
The largest trade he's ever made was buying 12,000 units of abrdn Healthcare Opportunities Fund stock on 20 September 2023 worth over 152,160$. On average, Daniel trades about 4,658 units every 146 days since 2004. As of 25 September 2023 he still owns at least 197,518 units of abrdn Healthcare Opportunities Fund stock.
You can see the complete history of Mr. Omstead stock trades at the bottom of the page.
Daniel R. Omstead Ph.D. serves as President, Trustee of the Company., He is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to the Funds. Dr. Omstead is also President of the Funds and serves on their Valuation Committee. Dr. Omstead is portfolio manager for the public and restricted/venture portfolios within the Funds. As part of these responsibilities, Dr. Omstead is a member of the Board of Directors of a portfolio company, IlluminOss Medical, Inc. Prior to joining the Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck & Co., Inc. Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies. Dr. Omstead holds Ph.D. and Master's Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University. He is an emeritus member of the Board of Directors of a non-profit agency that provides emergency shelter, housing and supportive services to homeless and low-income individuals and families in the Boston area. Dr. Omstead was also a member of the Board of Trustees at the Joslin Diabetes Center.
Daniel Omstead is 67, he's been the President、 Trustee of abrdn Healthcare Opportunities Fund since 2014. There are 5 older and 1 younger executives at abrdn Healthcare Opportunities Fund. The oldest executive at abrdn Healthcare Opportunities Fund is William Reardon, 74, who is the Independent Trustees.
Daniel's mailing address filed with the SEC is C/O TEKLA HEALTHCARE INVESTORS, 100 FEDERAL STREET, 19TH FLOOR, BOSTON, MA, 02110.
Over the last 10 years, insiders at abrdn Healthcare Opportunities Fund have traded over 0$ worth of abrdn Healthcare Opportunities Fund stock and bought 44,516 units worth 798,865$ . The most active insiders traders include Daniel R Omstead、Jeffrey Allen Bailey、Michael W Bonney. On average, abrdn Healthcare Opportunities Fund executives and independent directors trade stock every 214 days with the average trade being worth of 56,911$. The most recent stock trade was executed by Rose Di Martino on 16 July 2024, trading 1,000 units of THQ stock currently worth 21,300$.
tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form
abrdn Healthcare Opportunities Fund executives and other stock owners filed with the SEC include: